ArticleBMC nephrology2026
A pilot study of Galectin-3 targeting in chronic kidney fibrosis and kidney function decline.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRenal fibrosis is a key feature of chronic kidney disease (CKD), driven by persistent inflammation, immune activation, and extracellular matrix accumulation. Galectin-3, a lectin involved in immune regulation and fibrosis, has been implicated in CKD progression, but its clinical and mechanistic roles remain incompletely defined.
methodsGalectin-3 expression was assessed in human CKD cohorts and correlated with renal function. Functional studies were performed in murine adenine-induced nephropathy and unilateral ureteral obstruction (UUO) models. Genetic deletion of Galectin-3 and pharmacological inhibition using GB1107 were used to evaluate its role in renal injury. Kidney fibrosis, inflammation, and function were analyzed by histology, serum biochemistry, RNA sequencing, and molecular assays.
resultsGalectin-3 was significantly upregulated in diseased human kidneys and correlated with renal dysfunction. In mouse models, Galectin-3 was induced in injured tubular epithelial cells. Galectin-3 deficiency significantly reduced renal fibrosis, with decreased serum creatinine, blood urea nitrogen, and α-SMA expression. Transcriptomic analysis showed suppression of NF-κB signaling-related genes in knockout kidneys. Pharmacological inhibition with GB1107 similarly reduced fibrosis and improved renal function.
conclusionsGalectin-3 promotes renal fibrosis by enhancing inflammatory and pro-fibrotic signaling. Targeting Galectin-3 genetically or pharmacologically may represent a therapeutic strategy to preserve renal function and further studies are required to determine whether targeting Galectin-3 can limit CKD progression in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.